Medical Devices

31 tickers rated Hold in this theme
NewestHighest Score Ranks all matching reports in this category by score, highest first.
Agilent Technologies, Inc.
A·Healthcare
B ★★★Hold
Current$157.93
Target$172.64
Return+9.3%
Aug 29, 2026

Agilent is a high-quality, cash-generative tollbooth in life sciences and analytical instruments with rapid margin expansion, though investors must accept a steep valuation premium amid cyclical biotech capex headwinds and China trade risk.

Score
84
Becton, Dickinson and Company
BDX·Healthcare
B ★★★Hold
Current$211.88
Target$217.80
Return+2.8%
Nov 8, 2026

Becton Dickinson combines recurring medical-device demand, strong cash generation, and post-separation efficiency potential, but modest organic growth, leverage, and the recent stock-price recovery constrain near-term upside.

Score
74
Edwards Lifesciences Corporation
EW·Healthcare
B ★★★Hold
Current$102.14
Target$103.50
Return+1.3%
Nov 7, 2026

Edwards Lifesciences combines a durable TAVR franchise with fast-growing mitral and tricuspid therapies, but demanding cash-flow valuation and competition limit near-term upside despite strong clinical momentum.

Score
73
Boston Scientific Corporation
BSX·Healthcare
B ★★★Hold
Current$41.98
Target$51.20
Return+22.0%
Oct 31, 2026

Boston Scientific offers specialized medical-device franchises, strong cash generation, and recovery potential at a discounted valuation, but cardiovascular weakness, cybersecurity disruption, and Penumbra financing threaten near-term earnings growth.

Score
73
Thermo Fisher Scientific Inc.
TMO·Healthcare
B ★★★Hold
Current$673.82
Target$721.24
Return+7.0%
Oct 25, 2026

Thermo Fisher Scientific combines durable laboratory switching costs, recurring consumables, and recovering biopharma demand with strong cash generation, but demanding valuation and acquisition-related leverage limit near-term upside.

Score
73
Teleflex Incorporated
TFX·Healthcare
B ★★★Hold
Current$150.87
Target$164.10
Return+8.8%
Nov 8, 2026

Teleflex could unlock higher per-share earnings through portfolio simplification, debt reduction, and medical device innovation, but weak capital returns and uncertain recurring margins constrain the investment case.

Score
72
ICU Medical, Inc.
ICUI·Healthcare
B ★★★Hold
Current$172.11
Target$183.35
Return+6.5%
Nov 8, 2026

ICU Medical offers a credible infusion-therapy turnaround supported by recurring consumables and stronger cash flow, but modest ROIC, acquisition-related debt, and product-quality risks limit its margin of safety.

Score
72
Baxter International Inc.
BAX·Healthcare
B ★★★Hold
Current$23.00
Target$27.30
Return+18.7%
Nov 1, 2026

Baxter offers a discounted medical-products turnaround supported by recurring hospital demand, recovering cash flow and debt reduction, but elevated leverage and uncertain margin sustainability limit near-term conviction.

Score
72
Haemonetics Corporation
HAE·Healthcare
B ★★★Hold
Current$119.93
Target$127.16
Return+6.0%
Nov 8, 2026

Haemonetics offers recurring plasma disposables, improving cash generation, and new vascular closure growth opportunities, but its elevated historical valuation and CSL rollout dependence limit near-term upside.

Score
71
Bio-Rad Laboratories, Inc.
BIO·Healthcare
B ★★★Hold
Current$381.57
Target$397.83
Return+4.3%
Nov 7, 2026

Bio-Rad combines resilient clinical diagnostics, improving adjusted margins, and a valuable Sartorius stake, but weak Life Science demand and low operating returns limit near-term upside.

Score
71
Cardinal Health, Inc.
CAH·Healthcare
B ★★★Hold
Current$271.72
Target$258.00
Return-5.0%
Nov 8, 2026

Cardinal Health's entrenched pharmaceutical distribution network and expanding specialty services support durable earnings growth, but its historically elevated valuation and customer concentration limit near-term upside.

Score
70
Glaukos Corporation
GKOS·Healthcare
B ★★★Hold
Current$237.60
Target$208.45
Return-12.3%
Nov 2, 2026

Glaukos combines accelerating ophthalmic treatment adoption, differentiated clinical technology, and emerging profitability, but its premium valuation leaves limited room for commercialization or earnings disappointments.

Score
70